Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 1/20 | 0.40 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | CCND1 | P24385 | 3/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810592 | 0.89 | TUBB4A (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL538612 | 0.78 | HTT (0.41) | POLBKDM4EALDH1A1GAA | |
| SCHEMBL537678 | 0.74 | HRH4 (0.42) | KDM4EALDH1A1GAA | |
| SCHEMBL538300 | 0.74 | KDM4E (0.43) | POLBKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL2812926 | 0.74 | KDM4E (0.38) | POLBKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL2812222 | 0.74 | ACHE (0.41) | AXLTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2812428 | 0.74 | APP (0.42) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL2809667 | 0.72 | LTA4H (0.41) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL13131723 | 0.72 | HTR7 (0.39) | IDH2ALDH1A1 | |
| SCHEMBL2816669 | 0.72 | CDK4 (0.38) | MAPK7IDH2BTKCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | MAPK7 2047/4885IDH2 229/4885BTK 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.